Voyager Therapeutics Inc (VYGR)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $107.66M
Last updated: Nov 17, 2026 at 11:03 AM ET
Voyager Therapeutics Inc (VYGR) Earnings: Report Dates and Results
Voyager Therapeutics (VYGR) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, Voyager Therapeutics reported EPS of -$0.40, above the -$0.41 estimate. It beat the EPS estimate in 5 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
VYGR has an expected report date of Mar 8, 2027.
VYGR Earnings Call
The latest VYGR earnings call transcript on file is labeled 2024Q4.
Read the 2024Q4 transcriptEarnings History
Of the 39 quarters below that had an estimate, VYGR beat 25 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $4.01M, down 70.0% from $13.37M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.40 | -$0.41 | -$0.80 - -$0.28 | +2.44% | Beat | N/A | 10 | 3 up, 0 down | Nov 5, 2026 | $4.01M |
| Jun 30, 2026 | -$0.40 | -$0.55 | -$0.72 - -$0.40 | +27.27% | Beat | N/A | 9 | 1 up, 0 down | Aug 6, 2026 | $3.17M |
| Mar 31, 2026 | -$0.47 | -$0.53 | -$0.63 - -$0.28 | +11.32% | Beat | N/A | 9 | 3 up, 3 down | May 7, 2026 | $2.59M |
| Dec 31, 2025 | -$0.47 | -$0.51 | -$0.72 - -$0.33 | +7.93% | Beat | N/A | 11 | 2 up, 7 down | Mar 9, 2026 | $15.34M |
| Sep 30, 2025 | -$0.47 | -$0.52 | -$0.60 - -$0.32 | +9.62% | Beat | N/A | 10 | 4 up, 4 down | Nov 10, 2025 | $13.37M |
| Jun 30, 2025 | -$0.57 | -$0.52 | -$0.80 - -$0.31 | -9.62% | Miss | N/A | 11 | 1 up, 2 down | Aug 6, 2025 | $5.20M |
| Mar 31, 2025 | -$0.53 | -$0.44 | -$0.64 - -$0.17 | -20.45% | Miss | N/A | 10 | 4 up, 2 down | May 6, 2025 | $6.47M |
| Dec 31, 2024 | -$0.59 | -$0.35 | -$0.48 - -$0.13 | -68.43% | Miss | -147.2% | 10 | 4 up, 2 down | Mar 11, 2025 | $6.28M |
| Sep 30, 2024 | -$0.16 | -$0.40 | -$0.65 - -$0.08 | +60.00% | Beat | N/A | 10 | 0 up, 0 down | Nov 12, 2024 | $24.63M |
| Jun 30, 2024 | -$0.18 | -$0.40 | -$0.51 - -$0.22 | +55.00% | Beat | N/A | 10 | 0 up, 0 down | Aug 6, 2024 | $29.58M |
| Mar 31, 2024 | -$0.20 | -$0.42 | -$0.52 - -$0.31 | +52.38% | Beat | -106.8% | 9 | 0 up, 0 down | May 13, 2024 | $19.52M |
| Dec 31, 2023 | $1.25 | -$0.29 | -$0.62 - $1.33 | +531.03% | Beat | N/A | 7 | 0 up, 0 down | Feb 28, 2024 | $90.06M |
| Sep 30, 2023 | -$0.59 | -$0.60 | -$0.68 - -$0.47 | +1.67% | Beat | -231.1% | 7 | 0 up, 0 down | Nov 6, 2023 | $4.61M |
| Jun 30, 2023 | -$0.51 | -$0.56 | -$0.60 - -$0.52 | +8.93% | Beat | N/A | 7 | 0 up, 0 down | Aug 3, 2023 | $4.85M |
| Mar 31, 2023 | $2.94 | $1.26 | -$0.55 - $3.35 | +133.33% | Beat | N/A | 6 | 0 up, 0 down | May 9, 2023 | $150.48M |
| Dec 31, 2022 | -$0.61 | -$0.55 | -$0.75 - -$0.38 | -10.91% | Miss | -506.7% | 7 | 1 up, 0 down | Mar 7, 2023 | N/A |
| Sep 30, 2022 | $0.45 | -$0.41 | -$0.56 - $0.44 | +209.76% | Beat | N/A | 7 | 0 up, 0 down | Nov 8, 2022 | $41.09M |
| Jun 30, 2022 | -$0.50 | -$0.42 | N/A | -19.05% | Miss | N/A | N/A | 0 up, 0 down | Aug 4, 2022 | $712000 |
| Mar 31, 2022 | -$0.56 | -$0.34 | -$0.69 - $0.64 | -64.71% | Miss | N/A | 7 | 0 up, 0 down | May 4, 2022 | $658000 |
| Dec 31, 2021 | $0.15 | -$0.33 | -$0.72 - $0.17 | +145.45% | Beat | N/A | 9 | 0 up, 0 down | Mar 8, 2022 | $28.07M |
| Sep 30, 2021 | -$0.67 | -$0.73 | -$0.85 - -$0.59 | +8.22% | Beat | -129.5% | 8 | N/A | Nov 2, 2021 | $1.48M |
| Jun 30, 2021 | -$0.80 | -$0.68 | -$0.94 - -$0.56 | -17.65% | Miss | N/A | 8 | N/A | Aug 9, 2021 | $1.36M |
| Mar 31, 2021 | -$0.58 | -$0.66 | -$0.87 - -$0.34 | +12.12% | Beat | N/A | 10 | N/A | May 10, 2021 | $6.50M |
| Dec 31, 2020 | -$0.43 | -$0.57 | -$1.03 - -$0.07 | +24.56% | Beat | N/A | 12 | N/A | Feb 25, 2021 | $6.54M |
| Sep 30, 2020 | $2.27 | $0.20 | -$0.95 - $2.42 | N/A | N/A | N/A | 12 | N/A | Nov 9, 2020 | $117.84M |
| Jun 30, 2020 | -$0.23 | -$0.69 | -$0.92 - -$0.55 | +66.67% | Beat | -179.3% | 11 | N/A | Aug 10, 2020 | $28.68M |
| Mar 31, 2020 | -$0.66 | -$0.81 | -$1.13 - -$0.24 | +18.52% | Beat | N/A | 14 | N/A | May 6, 2020 | $18.07M |
| Dec 31, 2019 | -$0.34 | -$0.81 | -$1.12 - -$0.34 | +58.02% | Beat | N/A | 11 | N/A | Mar 3, 2020 | $32.67M |
| Sep 30, 2019 | -$0.41 | -$0.67 | -$1.00 - -$0.49 | +38.81% | Beat | N/A | 10 | N/A | Nov 6, 2019 | $20.43M |
| Jun 30, 2019 | $0.29 | -$0.80 | -$0.97 - -$0.48 | +136.25% | Beat | N/A | 11 | N/A | Aug 9, 2019 | $46.09M |
| Mar 31, 2019 | -$0.81 | $0.58 | -$0.94 - $4.73 | -239.66% | Miss | N/A | 10 | N/A | May 7, 2019 | $5.20M |
| Dec 31, 2018 | -$0.70 | -$0.71 | -$0.95 - -$0.55 | +1.41% | Beat | N/A | 9 | N/A | Feb 26, 2019 | $2.01M |
| Sep 30, 2018 | -$0.63 | -$0.76 | -$0.94 - -$0.46 | +17.11% | Beat | N/A | 9 | N/A | Nov 7, 2018 | $2.09M |
| Jun 30, 2018 | -$0.80 | -$0.66 | -$0.80 - -$0.47 | -21.21% | Miss | N/A | 9 | N/A | Aug 7, 2018 | $2.58M |
| Mar 31, 2018 | -$0.63 | -$0.61 | -$0.77 - $1.38 | -3.28% | Miss | N/A | 9 | N/A | May 10, 2018 | $942000 |
| Dec 31, 2017 | -$0.40 | -$0.72 | -$0.92 - -$0.48 | +44.44% | Beat | N/A | 10 | N/A | Mar 14, 2018 | $6.35M |
| Sep 30, 2017 | -$0.89 | -$0.71 | -$0.82 - -$0.48 | -25.35% | Miss | N/A | 10 | N/A | Nov 2, 2017 | $1.15M |
| Jun 30, 2017 | -$0.73 | -$0.59 | -$0.74 - -$0.48 | -23.73% | Miss | N/A | 5 | N/A | Aug 8, 2017 | $1.18M |
| Mar 31, 2017 | -$0.65 | -$0.53 | N/A | -22.64% | Miss | N/A | N/A | N/A | May 9, 2017 | $1.46M |
| Dec 31, 2016 | -$0.57 | -$0.45 | N/A | -26.67% | Miss | N/A | N/A | N/A | Mar 15, 2017 | $2.36M |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.04, after -$1.13 the year before. It was -$1.58 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.04 | N/A |
| Dec 31, 2024 | -$1.13 | -136.6% |
| Dec 31, 2023 | $3.09 | N/A |
| Dec 31, 2022 | -$1.22 | N/A |
| Dec 31, 2021 | -$1.90 | -300.0% |
| Dec 31, 2020 | $0.95 | N/A |
| Dec 31, 2019 | -$1.27 | N/A |
| Dec 31, 2018 | -$2.76 | N/A |
| Dec 31, 2017 | -$2.67 | N/A |
| Dec 31, 2016 | -$1.58 | N/A |
Earnings Calls
The 3 most recent earnings calls are listed below; the latest, 2024Q4 for the period ended Dec 31, 2024, runs about 7,300 words across 18 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q4 | Dec 31, 2024 | 7,284 | 18 | |
| 2024Q3 | Sep 30, 2024 | 5,180 | 12 | |
| 2024Q2 | Jun 30, 2024 | 5,772 | 14 |
2024Q4 Earnings Call
Opening remarks
Trista Morrison Chief Corporate Affairs Officer Good afternoon. We issued our fourth quarter and year-end 2024 financial results press release this afternoon. The press release and 10-K are available on our website. On today's call, Dr. Al Sandrock, our Chief Executive Officer, will briefly review key recent and upcoming milestones, and we will reserve most of our time for your Q&A. Joining us for Q&A are Dr. Toby Ferguson, our Chief Medical Officer; Dr. Todd Carter, our Chief Scientific Officer; and Dr. Nathan Jorgensen, our Chief Financial Officer. Before we get started, I would like to remind everyone that during this call, Voyager representatives may make forward-looking statements, as noted in Slide 2 of today's deck. These statements are based on our current expectations and beliefs. They are subject to risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors discussed in our SEC filings, which are available on our website for additional detail. Now, I will turn the call over to Al.
Alfred Sandrock Chief Executive Officer Good afternoon, everyone, and thank you for joining us. As Trista said, we plan to keep our remarks brief and prioritize your questions. On Slide 3, I want to remind you of why we're so excited about Voyager. Our pipeline includes four wholly owned and 13 partnered programs. We have already begun to generate clinical data, and we have multiple opportunities to generate more in the coming years. We are particularly excited about our two wholly owned programs targeting tau, which we view as the most important target in Alzheimer's disease. We also have two platforms to enable CNS delivery. I think most of you are familiar with our TRACER capsid platform for IV-delivered, CNS-targeted gene therapies. We are also generating data with our ALPL-based non-viral shuttle. I am hopeful we will be able to share some of that data with you later this year. Finally, our partnerships have been a significant source of non-dilutive revenue for us. That's the big reason we are able to report $332 million in cash as of the end of 2024. And with $8.2 billion in potential future milestone payments, we believe partnerships will continue to contribute significantly to our bottom line. As I always say, we are open for additional business. We are always discussing new partnership opportunities. While we are building a multimodality neurotherapeutics company here, I want to make a comment about gene therapy, which comprises much of our current pipeline. Despite continued setbacks in the field, it is possible to create a gene therapy that drives value for patients and investors. Zolgensma proves this.
Frequently Asked Questions About VYGR
When is Voyager Therapeutics's next earnings date?
Voyager Therapeutics's next earnings report is expected for Mar 8, 2027.
Did VYGR beat earnings estimates last quarter?
Yes. Voyager Therapeutics reported EPS of -$0.40 for the quarter ended Sep 30, 2026, above the -$0.41 estimate, a 2.44% surprise.
What EPS do analysts expect from VYGR next quarter?
The consensus EPS estimate for Voyager Therapeutics for the quarter ending Dec 31, 2026 is -$0.42 from 13 analysts, with estimates from -$0.88 to -$0.08.
How often does VYGR beat earnings estimates?
Voyager Therapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of -4.99%.
VYGR pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors